

Special Issue

Drug Treatment for Epilepsy

Message from the Guest Editor

Each year, new advances in the treatment of epilepsy highlight the dynamic progress in neuroscience, pharmacology, and precision medicine. The FDA continues to approve novel compounds—ranging from small molecules to biologics and gene-targeted therapies—that demonstrate both innovation and unmet clinical needs in seizure management. While small molecules remain the cornerstone of antiepileptic therapy, the emergence of antibody-based treatments, neuropeptides, and RNA-based drugs is expanding the therapeutic landscape. Particularly noteworthy is the increased attention being given to drug-resistant epilepsy, rare epileptic syndromes, and personalized treatment strategies, often addressed through orphan drug development and the targeted modulation of specific pathways. The aim of this Special Issue is to provide our readers with short, up-to-date reviews on emerging and approved antiepileptic drugs that are reshaping clinical practice. We welcome contributions that focus on mechanisms of action, clinical efficacy, safety profiles, and the translational journey from bench to bedside.

Guest Editor

Dr. Clarissa Fantin Cavarsan

Neuroscience and Behavior Program, Wesleyan University, Middletown, CT 06459, USA

Deadline for manuscript submissions

25 February 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/252558

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)